Use of Extracorporeal Photopheresis in Kidney Transplantation: Effects on Antibody-Mediated Rejec… (NCT07663669) | Clinical Trial Compass
RecruitingNot Applicable
Use of Extracorporeal Photopheresis in Kidney Transplantation: Effects on Antibody-Mediated Rejection
France31 participantsStarted 2026-06
Plain-language summary
This study aims to describe, over a one-year period, the clinical, biological, and histological evolution of a cohort of kidney transplant recipients who developed antibody-mediated rejection and were treated with extracorporeal photopheresis.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Kidney transplant recipients followed at the University Hospitals of Besançon and Lille between September 1, 2016, and August 31, 2023
* Patients with antibody-mediated rejection (as confirmed by histological analysis of the renal biopsy)
* Rejection treated with extracorporeal photopheresis
* Subjects who do not object to the use of their personal data and/or biological samples
* Subjects affiliated with, or beneficiaries of, the French social security system
Exclusion Criteria:
* Patients with acute rejection
* Pregnant women, women in labor, or breastfeeding mothers
* Individuals deprived of liberty by judicial or administrative decision; individuals receiving compulsory psychiatric care; or individuals admitted to a healthcare or social institution for reasons other than research participation
* Minors
* Adults under legal protection or unable to provide informed consent
* Subjects without health insurance coverage
* Subjects currently within an exclusion period from another study, or as listed in the "national volunteer registry"
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Number of participants with response to extracorporeal photopheresis (ECP) at 1 year
Timeframe: One year after initiation of ECP
Trial details
NCT IDNCT07663669
SponsorCentre Hospitalier Universitaire de Besancon